Complement factor H or a related protein is a marker for transitional cell cancer of the bladder.

Robert J. Kinders(National Cancer Institute), G. Michael Hass, Michael J. Corey, Tiffanie K. Jones(University of Pennsylvania), David L. Enfield, H.A. Murchison, L. Williams, Richard K. Root, Connie L. Bruce

PubMed

October 1, 1998

Cited by 128

Related Papers

Comprehensive mapping of immune perturbations associated with severe COVID-19

|Science Immunology|2020|806

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

|Nature Medicine|2021|521

A Randomized Clinical Trial of Granulocyte Transfusions for Infection in Acute Leukemia

|New England Journal of Medicine|1977|299

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors

|Journal of Clinical Oncology|2017|177

Post–Acute Care Use and Hospital Readmission after Sepsis

|Annals of the American Thoracic Society|2015|137